RecruitingNCT06060041

IC-8 Apthera IOL New Enrollment Post Approval Study

Studying NLRP3-associated autoinflammatory disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Bausch & Lomb Incorporated
Enrollment
435 target
Eligibility
22 years · All sexes
Timeline
20232027

Study locations (14)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06060041 on ClinicalTrials.gov

Other trials for NLRP3-associated autoinflammatory disease

Additional recruiting or active studies for the same condition.

See all trials for NLRP3-associated autoinflammatory disease

← Back to all trials